TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11127250
Drug: Paromomycin (PM)
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin (PM) 12 mg/kg daily plus Sodium Stibogluconate (SB) 20 mg/kg daily for 21 days
Study: 11127250
Drug: Paromomycin (PM)
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin (PM) 18 mg/kg daily plus Sodium Stibogluconate (SB) 20 mg/kg daily for 21 days
Study: 8474811
Drug: Iron-fortified formula
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified formula with 12.7 mg/L iron
Study: 8474811
Drug: Iron-fortified formula
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified formula with 7.4 mg/L iron
Study: 3082347
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg SCG aerosol
Study: 3082347
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg SCG aerosol
Study: 3082347
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg SCG aerosol
Study: 3082347
Drug: Nebulised SCG
Normalized name: microcrystalline cellulose 102 SCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised SCG (10 g l‐1)
Study: 30467952
Drug: Mildly increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildly increased uACR (≥10 mg/g <30 mg/g)
Study: 30467952
Drug: Mildly increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildly increased uACR (≥10 mg/g <30 mg/g) in nonwhites
Study: 27284115
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation therapy using the frontal/executive program for about six months
Study: 27284115
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation therapy using the frontal/executive program
Study: 24493413
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of delayed (123)I-MIBG scintigraphy and FMD
Study: 20493957
Drug: Doxycycline (100mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100mg, twice daily)
Study: 27317093
Drug: febuxostat (10-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: febuxostat (10-60 mg/day)
Study: 27317093
Drug: non-pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-pharmacological treatment
Study: 20206354
Drug: 200mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg of oral mifepristone followed 2 days later by 400 microg of sublingual misoprostol
Study: 17873260
Drug: DA +
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA + Coaching (DA + CC)
Study: 17873260
Drug: DA +
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA + CC
Study: 10952840
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (bolus of 5000 IU followed by an infusion of 1200 IU.h(‐1))
Study: 10952840
Drug: Low-dose hirudin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hirudin (0.2 mg.kg(‐1) bolus followed by 0.10 mg.kg(‐1).h(‐1))
Study: 10952840
Drug: Medium-dose hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose hirudin (0.4 mg.kg(‐1) bolus followed by 0.15 mg.kg(‐1).h(‐1))
Study: 8393055
Drug: Acyclovir prophylaxis
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir prophylaxis and ganciclovir treatment (group 3)
Study: 8393055
Drug: Prophylaxis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis and treatment with ganciclovir (group 4)
Study: 3088298
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using carmofur (HCFU), mitomycin C (MMC) and immunopotentiators (group B)
Study: 27450552
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folate supplements
Study: 24581069
Drug: Experimental nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental nicotine vaccine
Study: 21067660
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS), 200 micrograms, single dose
Study: 21067660
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS), 200 micrograms, for 6 days
Study: 10674617
Drug: IGF‐I/BP‐3 complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I/BP‐3 complex (1 to 4 mg/kg/day for 5 days)
Study: 8970458
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dihydroergotamine mesylate
Study: 8970458
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg dihydroergotamine mesylate
Study: 22433939
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin
Study: 30726533
Drug: Ortataxel 75
Normalized name: Ortataxel
DrugBank: Ortataxel (DB11669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortataxel 75 mg/m2 i.v. every 3 weeks until disease progression
Study: 28370614
Drug: High-dose concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose concurrent chemoradiotherapy (CRT)
Study: 28370614
Drug: Low-dose concurrent
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose concurrent chemoradiotherapy (CRT)
Study: 19121921
Drug: Regulat (fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regulat (fermented food concentrate) taken twice daily for 4 weeks
Study: 9259399
Drug: ICI 182780
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 182780 (ICI) 6 or 18 mg/day
Study: 9259399
Drug: Non-treatment (NT)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment (NT) control group
Study: 8503668
Drug: Shuang Huang
Normalized name: Jiang Huang (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuang Huang Lian herbs with antibiotics
Study: 15320644
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of partial and full range of motion training (Group 3: N = 30)
Study: 2503295
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing 50 ug of ethinyl estradiol combined with 250 mg levonorgestrel
Study: 2503295
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing 30 ug of ethinyl estradiol combined with 250 mg levonorgestrel
Study: 797410
Drug: fenoterol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol (400 mug) and SCH 1000 (40 mug) combination
Study: 26419668
Drug: Dapaconazole tosylate
Normalized name: Itraconazole
DrugBank: Dapaconazole (DB11985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapaconazole tosylate 2% cream
Study: 23793133
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (4.5 g green tea/330 ml, providing approximately 400 mg catechins)
Study: 8549572
Drug: Water (330
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (330 ml)
Study: 15451390
Drug: SGS742 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGS742 (600 mg t.i.d. for 8 weeks)
Study: 11819837
Drug: Intraluminal stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal stent installation combined with intra-arterial drug infusion
Study: 29580220
Drug: Face-to-face trauma-focused
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face trauma-focused cognitive behaviour therapy (TFCBT)
Study: 22678090
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure-lowering treatment
Study: 25478237
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (sham group)
Study: 18716735
Drug: Diepoxybutane 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diepoxybutane 0.1 mug/ml
Study: 18716735
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C 0.1 microg/ml
Study: 1641050
Drug: Protocol I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol I: 240 mg paracetamol
Study: 1641050
Drug: Protocol II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol II: 500 mg paracetamol
Study: 1641050
Drug: Protocol III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol III: 500 mg paracetamol plus 10 mg codeine
Study: 6381269
Drug: Proglumetacin 450
Normalized name: proglumetacin
DrugBank: Proglumetacin (DB13527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumetacin 450 mg/day (150 mg in the morning, 300 mg in the evening)
Study: 6381269
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg/day (placebo in the morning, 20 mg in the evening)
Study: 27215455
Drug: CT guided
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT guided radiofrequency ablation followed by intratumoral chemotherapy (RFA-ITC)
Study: 15902994
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg/day
Study: 12920428
Drug: Self-selected music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected music therapy (n = 100)
Study: 10505693
Drug: VPA-985 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA-985 (250 mg)
Study: 8941477
Drug: LysB28, ProB29-human
Approvals — FDA: no, EMA: no, PMDA: no
Description: LysB28, ProB29-human insulin analogue (lispro)
Study: 6810843
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin sodium, 5,000 IU/6 hr
Study: 7031568
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no heparin prophylaxis)
Study: 22484799
Drug: arzoxifene 20
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: arzoxifene 20 mg/day
Study: 18771352
Drug: Control (dacarbazine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (dacarbazine-based chemotherapy)
Study: 15328774
Drug: Standard Thai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Thai passages with a mixture of oral and nasal consonants
Study: 9104520
Drug: Propofol patient-controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol patient-controlled sedation (PCS) at a dose of 0.3 mg.kg-1, delay = three min (n = 20)
Study: 9104520
Drug: Anaesthetist-administered midazolam-fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anaesthetist-administered midazolam-fentanyl sedation (n = 20)
Study: 8471416
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate MF701 (2 mg kg‐1)
Study: 8471416
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate MF701 (2.5 and 3 mg kg‐1)
Study: 8471416
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate MF701 (4.5 and 6 mg kg‐1)
Study: 8471416
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate MF701 (all doses)
Study: 12712782
Drug: Propofol total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol total intravenous anaesthesia
Study: 26861608
Drug: Everolimus (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (5 mg per day) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for a total of six cycles
Study: 21806467
Drug: Protraction Face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protraction Face Mask (PFM) therapy
Study: 21806467
Drug: Reverse Twin-Block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reverse Twin-Block (RTB) therapy
Study: 21244738
Drug: Intranasal oxymetazoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxymetazoline (0.05% OMZ, 45 μL containing 22.5 μg of OMZ hydrochloride)
Study: 21244738
Drug: Intranasal oxymetazoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxymetazoline (0.05% OMZ)
Study: 12131352
Drug: Intravesical morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical morphine (0.04 mg/kg/hour)
Study: 2383364
Drug: 0.25% CHP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% CHP cream
Study: 2383364
Drug: 0.5% CHP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% CHP cream
Study: 2383364
Drug: 1% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% silver sulphadiazine (AgSD) cream
Study: 2383364
Drug: 2% CHP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CHP cream
Study: 7219904
Drug: Prophylactic antihypertensive
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antihypertensive agents (placebo, hydralazine, or methyldopa)
Study: 25643050
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg once daily) administered on days 11-14 with erlotinib (150 mg) on day 15
Study: 25643050
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg once daily) administered in the morning for 5 days, 2 h before erlotinib (150 mg)
Study: 25643050
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice daily) administered for 5 days, with staggered dosing of erlotinib (150 mg)
Study: 20220184
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (400 microg/kg)
Study: 3512461
Drug: 0.5% malathion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% malathion lotion
Study: 17600607
Drug: Olanzapine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (20 mg/day and 30 mg/day)
Study: 12004990
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (0.05, 0.1, 0.2, and 0.3 microg x k(‐1) x min(‐1))
Study: 12004990
Drug: Low-dose epinephrine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose epinephrine (0.05 microg x kg(‐1) x min(‐1))
Study: 12004990
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine
Study: 10661631
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate (SP) solution
Study: 7788955
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg/kg) administered intravenously over 10 min
Study: 2365041
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg terbutaline nebulized twice daily for 2 + 2 weeks
Study: 2365041
Drug: Placebo nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nebulized twice daily for 2 + 2 weeks
Study: 6802260
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily for 2 months
Study: 6802260
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily for 5 months
Study: 29158664
Drug: Nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine gastrointestinal therapeutic system (NGTS) administered for 24 weeks, with a possible uptitration to 60 mg/d after 4 weeks if BP reduction was unsatisfactory.
Study: 15875127
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg x kg(‐1) propofol
Study: 12825997
Drug: Flutrimazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutrimazole 1% twice daily (TD)
Study: 12825997
Drug: Flutrimazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutrimazole 1% once daily (OD)
Study: 9460336
Drug: Mitoxantrone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (12 mg/m2 i.v., day 1), 5‐fluorouracil (350 mg/m2 i.v. days 1‐3), leucovorin (300 mg i.v. days 1‐3)
Study: 9460336
Drug: Paclitaxel (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (135 mg/m2 i.v. 1‐h infusion) added to NFL regimen
Study: 9460336
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF regimen (cyclophosphamide 600 mg/m2 i.v. day 1, methotrexate 40 mg/m2 day 1; 5FU 600 mg/m2 i.v. day 1)
Study: 8203993
Drug: Beef (85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef (85 g of cooked beef, 8% fat)
Study: 8203993
Drug: Chicken (85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken (85 g of cooked chicken, 7% fat)
Study: 3294814
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) 50 mg combined with dexamethasone 1 mg in single capsules
Study: 30016935
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of Dialectical Behaviour Therapy (DBT)
Study: 30016935
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of Dialectical Behaviour Therapy (DBT)
Study: 26903390
Drug: Oral Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Indomethacin
Study: 24485847
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with bupropion (max 450 mg/d) and escitalopram (max 40 mg/d) for 12 weeks
Study: 31744781
Drug: Bupropion monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion monotherapy
Study: 22568663
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg immediate release (IR) oxycodone
Study: 22568663
Drug: Crushed 40
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed 40 mg controlled release (CR) oxycodone
Study: 22568663
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg controlled release (CR) oxycodone
Study: 22568663
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg controlled release (CR) oxycodone
Study: 20138720
Drug: High-dose levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose levocabastine nasal spray
Study: 20138720
Drug: Low-dose levocabastine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose levocabastine nasal spray
Study: 15780139
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural group intervention (8 weekly sessions of 2 hours each and a booster session)
Study: 11783208
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Traditional Chinese Medicine (TCM)
Study: 11783208
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus Traditional Chinese Medicine (TCM)
Study: 8538929
Drug: Omeprazole 60
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 60 mg/day
Study: 1768560
Drug: ICS 205-930
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS 205-930 (0.15-0.18 mg kg-1, infused i.v.)
Study: 24461572
Drug: Oral stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral stimulation program for 15 min at least for 10 days before introduction of oral feeding
Study: 17693960
Drug: Diet C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet C: day/night formulas administered in synchrony with the environment
Study: 16296426
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment (HealOzone) applied once for 40 seconds to the test molar.
Study: 7999657
Drug: Patient-assisted epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-assisted epidural analgesia (fentanyl 10 mcg/mL and bupivacaine 1 mg/mL for the first 2 days)
Study: 30882524
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion
Study: 27876528
Drug: Polyhexamethylene biguanide
Normalized name: Polyhexamethylene Biguanide
DrugBank: Polihexanide (DB12277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyhexamethylene biguanide (PHMB) preserved multipurpose care solution (MPS)
Study: 27876528
Drug: Peroxide-based solution
Normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroxide-based solution system
Study: 27876528
Drug: Solution-induced corneal
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-induced corneal staining (SICS)
Study: 15037937
Drug: Topical 0.2
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2 percent nitroglycerin ointment
Study: 1634646
Drug: Nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 5 mg
Study: 1634646
Drug: Nisoldipine 20
Normalized name: nisoldipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 20 mg
Study: 31529590
Drug: Apixaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (2.5 mg twice daily)